Cholera: Clinical Trials

17 trials for Cholera, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

17 completed. 17 Phase 2, 2 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 217Completed 17
Phase 12Completed 2
Phase 31Completed 1

Follow Cholera: new trials by email Literature Review of Cholera trials Research Report on Cholera

Trials (filtered) newest first · largest first

All 17 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera
VR-AD-1005, Placebo - Cholera
Phase 2CompletedHunazine Biotech S.L.1502024-02-112026-06-02
Next Generation ORS: Comparing ORS With Calcium vs Standard ORS in Reducing Severity of Acute Watery Diarrhea
Next Generation ORS (oral rehydration solution) (including placebo, Current standard control ORS (oral rehydration solution) - Diarrhea, Cholera
Phase 2 / Phase 3CompletedUniversity of Florida3962023-08-212026-04-14
Single Dose Azithromycin to Prevent Cholera in Children
Azithromycin, Placebo - Cholera
Phase 2CompletedMassachusetts General Hospital24752021-10-312026-08-07
Cholera Anti-Secretory Treatment Trial
iOWH032, Placebo, V. cholerae Challenge - Cholera
Phase 2CompletedPATH472019-11-042021-03-25
Extended Dose Intervals With Oral Cholera Vaccine in Cameroon
killed whole cell oral cholera vaccine - Adverse Reaction to Cholera Vaccine, Cholera Vaccination Reaction
Phase 2CompletedJohns Hopkins Bloomberg School of Public Health1812018-10-232022-10-05
Immunologic Responses to a Live Attenuated Oral Cholera Vaccine
Vaxchora - Cholera
Phase 2CompletedEmory University342017-08-292026-02-13
Safety and Immunogenicity of Locally Manufactured New (HL-OCV) Oral Cholera Vaccine
HL-OCV, Shanchol - Cholera
Phase 1 / Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh8402016-07-012018-11-02
Safety and Immunogenicity of Locally Manufactured Oral Cholera Vaccine
Cholvax, Shanchol - Cholera
Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh20522016-04-012017-06-16
PXVX0200 (CVD103-HgR) vs Shanchol in Mali
PXVX0200 10E8, PXVX0200 10E9, Placebo - Cholera
Phase 2CompletedUniversity of Maryland, Baltimore1502014-07-012019-09-26
Slow Versus Rapid Rehydration of Severely Malnourished Children
Rapid dehydration, Slow rehydration - Diarrhea
Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh2082011-05-012014-08-21
Study of Alternative Vaccination Schedule of Oral Cholera Vaccine
Modified killed oral cholera vaccine at 14 day interval, Modified killed oral cholera vaccine at 28 day interval - Cholera, Diarrhoea
Phase 2CompletedInternational Vaccine Institute3862010-12-012013-09-25
Safety and Immunogenicity of Single Dose Choleragarde® in HIV-Seropositive Adults
CholeraGarde®, Placebo - Cholera, Vibrio Infections
Phase 2CompletedInternational Vaccine Institute322010-07-012012-03-30
Studies of Immune Responses to Orally Administered Vaccines in Developing Country
Placebo, Control, Zinc Sulphate - Cholera, Typhoid
Phase 1 / Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh10162008-02-012011-07-12
Immunogenicity of One Versus Two Doses of Killed Oral Cholera Vaccine
Killed bivalent whole cell oral cholera vaccine, Heat Killed E. coli Placebo - Cholera, Diarrhea
Phase 2CompletedInternational Vaccine Institute1602007-06-012009-12-07
Safety and Immunogenicity of Oral Cholera Vaccine in Kolkata
killed whole cell oral cholera vaccine, Heat Killed E. coli - Cholera
Phase 2CompletedInternational Vaccine Institute2002005-08-012008-07-04
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
killed oral cholera vaccine - Cholera
Phase 2CompletedInternational Vaccine Institute1502005-05-012006-11-10
Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults
Benefiber, Benefiber with ORS, the reduced-osmolarity WHO-ORS without added Benefiber - Cholera
Phase 2CompletedInternational Centre for Diarrhoeal Disease Research, Bangladesh1952003-05-012008-05-06

Narrower conditions

Diarrhea (5)  ·  Vibrio Infections (3)  ·  Communicable Diseases (1)  ·  Dehydration (1)  ·  Malnutrition (1)  ·  Osteoarthritis (1)  ·  Typhoid Fever (1)

Broader conditions

Bacterial Infections (17)  ·  Bacterial Infections and Mycoses (17)  ·  Gram-Negative Bacterial Infections (17)  ·  Infections (17)  ·  Vibrio Infections (14)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Signs and Symptoms (5)  ·  Signs and Symptoms, Digestive (5)  ·  Pathologic Processes (2)  ·  Arthritis (1)  ·  Disease Attributes (1)  ·  Enterobacteriaceae Infections (1)  ·  Joint Diseases (1)  ·  Metabolic Diseases (1)  ·  Musculoskeletal Diseases (1)

Interventions

shanchol (4)  ·  Albendazole (1)  ·  Anti-Bacterial Agents (1)  ·  Arsenic (1)  ·  Azithromycin (1)  ·  Calcium (1)  ·  IOWH-032 (1)  ·  ORALIT (1)  ·  Peru 15 (1)  ·  Vaxchora (1)  ·  World Health Organization oral rehydration solution (1)  ·  Zinc Sulfate (1)  ·  secnidazole (1)

Sponsors

International Centre for Diarrhoeal Disease Research, Bangladesh (5)  ·  International Vaccine Institute (5)  ·  Emory University (1)  ·  Hunazine Biotech S.L. (1)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  Massachusetts General Hospital (1)  ·  PATH (1)  ·  University of Florida (1)  ·  University of Maryland, Baltimore (1)

Countries

Bangladesh (8)  ·  India (3)  ·  United States (2)  ·  Cameroon (1)  ·  Mali (1)  ·  Thailand (1)  ·  Vietnam (1)

Top investigators

Firdausi Qadri, Dr. (2)  ·  Dang Duc Anh, PhD (1)  ·  David Sack, MD (1)  ·  Dipika Sur, MD, DPH (1)  ·  Firdausi Qadri, PhD (1)  ·  Jason B Harris, MD, MPH (1)  ·  Milagritos D Tapia, MD (1)  ·  Nadine Rouphael, MD (1)  ·  Sam Cheng, MD. PhD (1)  ·  Samba O Sow, MD, MS (1)  ·  Sujit K Bhattacharya (1)  ·  Sujit K Bhatttacharya, MD (1)  ·  Winai Ratanasuwan, MD, MPH (1)

Results publications

PMID 22461716, PMID 16760521, PMID 17055622, PMID 18398491, PMID 18769066, PMID 19761838, PMID 21907255, PMID 24101640, PMID 29021299, PMID 34218960, PMID 34478460, PMID 34793441

NIH funding

R01AI137127 (1), R01HD102540 (1), R21AI169282 (1)